NEW YORK – The US Food and Drug Administration on Friday approved lisocabtagene maraleucel (Bristol Myers Squibb's Breyanzi) as a treatment for relapsed or refractory large B-cell lymphoma.
NEW YORK – The US Food and Drug Administration on Friday approved lisocabtagene maraleucel (Bristol Myers Squibb's Breyanzi) as a treatment for relapsed or refractory large B-cell lymphoma.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.